NFE2L2 and nonpapillary renal cell carcinoma: By binding with KEAP1, DPP9 promotes the stability of NRF2 and overcomes oxidative stress, and the accumulation of DPP9 can lead to the hyperactivation of the NRF2 pathway and inhibit ferroptosis, thereby driving ccRCC development and sorafenib resistance (68).